Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

December 2020

You'll hear buzz about using SGLT2 inhibitors (empagliflozin, etc) in patients withOUT diabetes...for heart failure or kidney disease.

That's because growing evidence suggests these meds may improve outcomes when added to standard therapy.

In heart failure with reduced ejection fraction (HFrEF), adding empagliflozin (Jardiance) over 16 months prevents hospitalization or CV death in about 1 in 14 type 2s...or 1 in 26 patients withOUT diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Infectious Diseases Understand Roles of Remdesivir and Dexamethasone for COVID-19
Venous Thromboembolism Answer Common Questions About VTE Treatment
Hemorrhage Feel Comfortable Sticking With NovoSeven RT Over Sevenfact
Benzodiazepines Consider Strategies for Safe Use of Benzodiazepines
Gastroenterology Don't Think of Meds as a Significant Source of Gluten
Pregnancy Explain the New FDA Warning About NSAIDs in Pregnancy
Parkinson's Disease Clarify the Role of Ongentys and Kynmobi for Parkinson's Disease
Diabetes Meds Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes
Multiple Sclerosis Watch for Patients Taking the New Oral Multiple Sclerosis Meds
Med Safety Watch for New Concentrations of IV Ephedrine and Phenylephrine

Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents